Pharmamarketeer

Novartis gets European approval to update Cosentyx label to include dosing flexibility in ankylosing spondylitis

Novartis, a leader in rheumatology and immuno─dermatology, announced that the European Commission (EC) has approved a label update for the up─titration of Cosentyx (secukinumab) to 300 mg for patients with active

Advertentie(s)